- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00534209
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
Phase I/II Clinical Trial of Immunotherapy With an Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer That Have Completed First Line Chemotherapy
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells.
PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IIIB or stage IV non-small cell lung cancer who have finished first-line chemotherapy.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
OUTLINE: This is a multicenter study.
- Phase I (single site [University of Miami Sylvester Comprehensive Cancer Center]): Patients receive allogeneic B7.1 and human leukocyte antigen-A1 (HLA-A1) transfected tumor cell vaccine intradermally (ID) in weeks 1, 3, and 5. Treatment repeats every 6 weeks for 2 courses. If no more than 1 of 6 patients experience a probable or definitively treatment related adverse effect (i.e., grade 2 autoimmune or grade 3-4 of any type), patients proceed to the phase II portion of the study. If 2 or more (out of 6) patients experience treatment related adverse effects the study stops.
Phase II (randomized): Patients are stratified according to study site (University of Miami Sylvester Comprehensive Cancer Center or Memorial Regional Hospital), type of prior first-line treatment (platinum and taxane vs platinum and gemcitabine), and presence of brain metastasis (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive allogeneic B7.1 and HLA-A1 transfected tumor cell vaccine ID in weeks 1, 3, and 5. Treatment repeats every 6 weeks for 2 courses.
- Arm II: Patients receive a placebo vaccine as in arm I. Patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for cluster of differentiation 8 (CD8), cluster of differentiation 4 (CD4), and natural killer cell (NK) response and peripheral blood lymphocytes (PBL) and T helper cell 1 (TH1)/T helper cell 2 (TH2) bias, including levels of interleukin (IL) IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, Interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) via ELISA.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 4 years, and then once a year thereafter.
PROJECTED ACCRUAL: A total of 66 patients (6 patients for phase I and 60 patients for phase II) will be accrued for this study.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Florida
-
Hollywood, Florida, Yhdysvallat, 33021
- Memorial Regional Hospital
-
Miami, Florida, Yhdysvallat, 33136
- University of Miami Sylvester Comprehensive Cancer Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
INCLUSION CRITERIA
- Patients with stage IIIB (non-candidates for radiation) or stage IV pathologically confirmed non-small cell carcinoma of the lung that completed 4-6 cycles of platinum based first line chemotherapy and achieved complete response (CR), partial response (PR) or stable disease.
- Last administration of chemotherapy occurred no later than 4 weeks prior to the enrollment date.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Renal Requirements: The calculated creatinine clearance must be at least 50 ml/min.
Pulmonary Function Requirements:
- All patients will undergo evaluation of pulmonary function prior to enrollment.
- Patients should have a Forced expiratory volume in 1 second (FEV1) more than 30% of the predicted value and/or Diffusing capacity (DLCO) more than 30% of the predicted value with a partial pressure of carbon dioxide (PCO2) < 45mm.
- Any patient enrolled in the protocol whose respiratory symptoms have experienced marked deterioration not related to a known cause (e.g. pneumonia, congestive heart failure (CHF) or pulmonary embolism (PE)) will have request pulmonary function test (PFT) evaluation and if the above parameters are seen will be excluded from the protocol.
- Age ≥ 18 years.
- Signed informed consent.
- Patients should have absolute neutrophil count (ANC) ≥ 1000/mm3; platelets (PLT) ≥ 80,000/mm3.
EXCLUSION CRITERIA:
- Small cell carcinoma of the lung.
- Existing autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease etc; colitis, inflammatory bowel disease or pancreatitis within 10 years of study.
- Other active malignancies present within the past three years, except for basal and/or squamous cell carcinoma(s) or in situ cervical cancer.
- Concomitant steroid or other immunosuppressive therapy.
- Active infection, or less than 7 days since therapy for acute infections.
- Pericardial effusion.
- Currently receiving chemotherapy for another condition (such as arthritis).
- Time elapsed greater than 4 weeks since last administration of first line chemotherapy for NSCLC.
- Active or symptomatic cardiac disease such as congestive heart failure, angina pectoris or recent myocardial infarction.
- Pregnant or lactating women (negative test for pregnancy required of women of childbearing potential).
- Refusal in fertile men or women to use effective birth control measures during and for six months after the completion of treatment on study.
- Known HIV infection
- Untreated or uncontrolled brain metastasis.
- Liver Enzymes greater than 3 times the institutional upper limit.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Arm I: Allogeneic B7.1/HLA-A1
Patients will receive Allogeneic B7.1/HLA-A1 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines. Given intradermally. |
Dose: At least 4x10^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
Muut nimet:
|
Placebo Comparator: Arm II: Placebo
Patients receive a placebo vaccine intradermally once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
|
Given intradermally
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Preliminary Safety Profile (Phase 1)
Aikaikkuna: Up to 13 weeks
|
This will include the number of patients experiencing toxicity over the course of treatment, characterized by type of toxicity and grade, and by the time of toxicity onset in relation to day of vaccination.
|
Up to 13 weeks
|
Progression-free Survival (Phase 2)
Aikaikkuna: Date of randomization to the earliest date of documented progression.
|
Date of randomization to the earliest date of documented progression.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Immune Response (CD8) in B7-vaccinated Participants as Compared to Controls. (Phase 2)
Aikaikkuna: About 13 weeks
|
Rate of immune response (CD8) in B-7 vaccinated participants reported for measurements taken immediately prior to vaccination (week 0) and throughout the two courses.
|
About 13 weeks
|
Relationship of CD8 Response in B7-vaccinated Patients to Their Progression-free Survival.(Phase 2)
Aikaikkuna: From Week 1 of Study Therapy until Death or Withdrawal of Consent
|
Relationship of CD8 response in B7-vaccinated patients to their progression-free survival.
Summarized by the median and range of follow up time for patients grouped according to disease status (progression/no progression) and vital status (died/alive at last contact).
|
From Week 1 of Study Therapy until Death or Withdrawal of Consent
|
Safety Profile (Phase 2)
Aikaikkuna: About 13 weeks
|
The rate of patients experiencing toxicity over the course of treatment will be characterized by type of toxicity and grade, and by the time of toxicity onset in relation to day of vaccination.
|
About 13 weeks
|
Response to Second-line Chemotherapy After Disease Progression (Phase 2)
Aikaikkuna: From Week 1 of Study Therapy until Death or Withdrawal of Consent
|
The percentage of patients experiencing a clinical response (complete response (CR), partial response (PR), stable disease (SD)) on second-line chemotherapy will be characterized for B7-vaccinated patients and controls.
|
From Week 1 of Study Therapy until Death or Withdrawal of Consent
|
Overall Survival (Phase 2)
Aikaikkuna: Date of randomization to the recorded date of death
|
The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that study participants are still alive.
|
Date of randomization to the recorded date of death
|
Correlative Immunological Studies in Study Participants (Phase 2)
Aikaikkuna: Baseline, Week 7 and Week 13
|
The time course of patients' adaptive immune response to B7 vaccination as compared to control vaccine will be characterized by their CD8, CD4, and NK response (measured by ELI-spots for interferon-gamma (IFN-γ), interleukin 4 (IL-4), and granzyme B secretion) measured prior to vaccination (i.e. at baseline) and over two courses of vaccination (measurements at week 7 and 13).
|
Baseline, Week 7 and Week 13
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojen puheenjohtaja: Luis E. Raez, MD, FACP, University of Miami Sylvester Comprehensive Cancer Center
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther. 2003 Nov;10(11):850-8. doi: 10.1038/sj.cgt.7700641.
- Frankowski DJ, Raez J, Manners I, Winnik MA, Khan SA, Spontak RJ. Formation of dispersed nanostructures from poly(ferrocenyldimethylsilane-b-dimethylsiloxane) nanotubes upon exposure to supercritical carbon dioxide. Langmuir. 2004 Oct 12;20(21):9304-14. doi: 10.1021/la049646l.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 20057158
- SCCC-2005042 (Muu tunniste: UM/Sylvester Comprehensive Cancer Center)
- WIRB-20051678 (Muu tunniste: Western IRB (WIRB))
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Keuhkosyöpä
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrytointiMetastaattinen keuhkojen ei-pienisolusyöpä | Tulenkestävä keuhkojen ei-pienisolusyöpä | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8Yhdysvallat
-
Philipps University Marburg Medical CenterAktiivinen, ei rekrytointiTransplantation LungItävalta, Saksa
-
Mansoura UniversityRekrytointi
-
Eben RosenthalRekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Keuhkokarsinooma | Metastaattinen pahanlaatuinen kasvain keuhkoissaYhdysvallat
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Keuhkojen ei-pienisolukarsinooma | Vaiheen III keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Vaiheen II keuhkosyöpä AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Vaiheen IIB keuhkosyöpä AJCC v8 | Vaiheen IIIA keuhkosyöpä AJCC v8 | Vaiheen IIIB... ja muut ehdotYhdysvallat
-
Centre Hospitalier Universitaire de BesanconBiothelisTuntematonSydänkirurgia | Kardiopulmonaalinen ohitus | Lung
-
The University of Hong KongRekrytointi
-
National Cancer Institute (NCI)ValmisLung | Rinta | Munasarja | Kohdunkaulan | MunuaisetYhdysvallat
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)LopetettuPienisoluinen keuhkosyöpä | Stage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8Yhdysvallat
Kliiniset tutkimukset Allogeneic B7.1/HLA-A1
-
Eckhard PodackPeruutettuEi-pienisoluinen keuhkosyöpä | NSCLC | Keuhkosyöpä | Ei-pienisoluinen keuhkosyöpä
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Valmis